Ephedrine Sulfate

HCID 5359318

Daten werden ergänzt – meist innerhalb einer Minute fertig

Grundinformationen

CAS
134-72-5
Standard-SMILES
CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O
InChIKey
CAVQBDOACNULDN-KHFUBBAMSA-N
Summenformel
C20H32N2O6S
Durchschnittliche Molmasse
428,5 g/mol
Monoisotopische Masse
428,19810774

Überblick

Ephedrine sulfate is a white microcrystalline powder. Odorless. Central nervous system stimulant.

Namen und Bezeichner

Bevorzugter Name
Ephedrine Sulfate
IUPAC
bis((1R,2S)-2-(methylamino)-1-phenylpropan-1-ol);sulfuric acid

Namen und Synonyme

EPHEDRINE SULFATEEphedrine sulphateIsofedrolAkovazl-Ephedrine sulfateCorphedraEphedrini sulfasU6X61U5ZEGEMERPHED(-)-Ephedrine sulfate (2:1) (salt)NCI-C55652Ephedrine sulfate (USP)
Weitere Namen anzeigen
Ephedrine sulfate [USP]1-Phenyl-2-methylamine-propanol-1-sulfateDTXSID6020565Expansyl1-alpha-(1-(Methylamino)ethyl)benzyl alcohol sulfateFranol PlusFranol-PlusBenzenemethanol, alpha-(1-(methylamino)ethyl)-, (R-(R*,S*))-, sulfate (2:1) (salt)

Datenbank-Bezeichner

CAS
134-72-5
PubChem CID
5359318
DTXSID
DTXSID6020565
ChEMBL
CHEMBL1523964
UNII
U6X61U5ZEG
EC Number
205-154-4

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

Polarare Oberfläche (TPSA)
148 Ų
H-Brücken-Donoren
6
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
6
Schwere Atome
29

Experimentelle und physikochemische Eigenschaften

Solubilitygreater than or equal to 100 mg/mL at 68 °F (NTP, 1992)
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point473 to 478 °F (decomposes) (NTP, 1992)
Physical DescriptionEphedrine sulfate is a white microcrystalline powder. Odorless. Central nervous system stimulant.

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (71.4%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P272, P280, P301+P316, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 147 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Regulation (EC) No 178/2002 (amended)

Status: Active Update: 17-07-2015 https://echa.europa.eu/registration-dossier/-/registered-dossier/11520

Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1 Eintrag

SYMPTOMS: Symptoms of exposure to this compound may include nervousness, headache, sweating, nausea and vomiting. Contact dermatitis may occur. Other symptoms include an increase in pulse rate and an increase in blood pressure. Exposure may cause irritation of the skin, eyes and respiratory tract, central nervous system effects, peripheral nervous system effects, loss of appetite, tremors and, in severe cases, convulsions, coma and death. Sleeplessness, restlessness and urinary retention may occur. This compound may cause excitation, insomnia, palpitation, tachycardia, precordial pain, cardiac arrhythmias, vertigo, dryness of the nose and throat, warmth, vesical sphincter spasm and urinary hesitation. It may also cause anxiety, extrasystoles, confusion and delirium. Other symptoms include chills, cyanosis, irritability, fever, suicidal behavior, mania, dilated pupils, blurred vision, opisthotonos, spasms, pulmonary edema, gasping respiration, respiratory failure and anuria. Exposure can lead to giddiness, thirst, difficulty in micturition, muscular weakness, hypertension and ventricular arrhythmias. Overexposure can cause paranoid psychoses, delusions and hallucinations. Mydriasis may occur.

Reactive GroupAlcohols and Polyols
Reactivity ProfileAqueous solution are slightly acidic. This chemical is incompatible with strong oxidizers. (NTP, 1992)
Air and Water ReactionsWater soluble.

Sicherheit und Schutzausrüstung

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
First Aid · 1 Eintrag

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 Eintrag

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Personal Protective Equipment (PPE) · 1 Eintrag

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

Toxikologische Informationen

Carcinogen Classification · 6 Einträge

Ephedrine Sulfate

TR-307: Toxicology and Carcinogenesis Studies of Ephedrine Sulfate (CASRN 134-72-5) in F344/N Rats and B6C3F1 Mice (Feed Studies) (1986 )

08/14/85

No Evidence

No Evidence

No Evidence

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ephedrine sulfate

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 2 Einträge

EPHEDRINE SULFATE

beta-Adrenergic Agonist [EPC]; alpha-Adrenergic Agonist [EPC]; Adrenergic alpha-Agonists [MoA]; Increased Norepinephrine Activity [PE]; Adrenergic beta-Agonists [MoA]; Norepinephrine Releasing Agent [EPC]

MeSH Pharmacological Classification · 4 Einträge

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs used to cause constriction of the blood vessels.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Verwendung und Herstellung

General Manufacturing InformationBenzenemethanol, .alpha.-[(1S)-1-(methylamino)ethyl]-, (.alpha.R)-, sulfate (2:1): ACTIVE

Zugehörige Reaktionen

1

Notizen zur Verbindung

Wird geladen…